Immune Checkpoint Inhibitors in Urothelial Carcinoma (Literature Review)

Immune Checkpoint Inhibitors in Urothelial Carcinoma (Literature Review)

Bladder cancer is globally considered as one of the most aggressive neoplasms. Traditionally, first-line therapy for metastatic urothelial carcinoma has remained unchanged over the past decades and has been based on combinations of cisplatin. Unfortunately, almost all patients eventually progress an...

Full description

Saved in:
Bibliographic Details
Main Authors: K. V. Menshikov, A. V. Sultanbaev, Sh. I. Musin, A. A. Izmailov, O. N. Lipatov, I. A. Menshikova, N. I. Sultanbaeva, E. V. Popova
Format: Article
Language:English
Published: Bashkir State Medical University 2022-10-01
Series:Креативная хирургия и онкология
Subjects:
urothelial carcinoma
bladder cancer
immune checkpoint inhibitors
chemotherapy
pembrolizumab
nivolumab
atezolizumab
avelumab
durvalumab
cisplatin
Online Access:https://www.surgonco.ru/jour/article/view/715
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.surgonco.ru/jour/article/view/715

Similar Items